Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 56.68

-2.4%

Dec 12 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who wrote (4355)	7/26/2001 12:20:09 PM
From: IRWIN JAMES FRANKEL	of 52153

I agree Peter. Here is my view of the statement. I now think that peak sales of Xopenex nebule should reach $400 million. That is without MDI which should be much bigger. For a mature product with great margins and long patent life, 6 to 8 times sales seems ball park for valuation. That is $2.4 to 3.2 billion. Allegra is doing run rate royalties of $44 million and all flows to the bottom line. Growing 40% (not sustainable) but could still be worth 15 to 20 times current annual royalties. So call it $600 million to $800 million. Total range $3 to $4 billion. ij

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next